Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.
ADVANCED SEARCH
Log in
Top
Current Fungal Infection Reports
Published in: Current Fungal Infection Reports 4/2018

01-12-2018 | Current Management of Fungal Infections (J Maertens, Section Editor)

Patients with Primary Immunodeficiencies: How Are They at Risk for Fungal Disease?

Authors: Giorgia Bucciol, Leen Moens, Isabelle Meyts

Published in: Current Fungal Infection Reports | Issue 4/2018

Login to get access

Abstract

Purpose of Review

In this review, we focus on the inborn errors of immunity known to render the host susceptible to fungal infections, including candidias, aspergillosis, dermatophytosis, phaeohyphomycosis, pneumocystosis, fusariosis, cryptococcosis, and endemic mycoses.

Recent Findings

Classically, the burden of fungal disease in humans is believed to be carried by patients with a secondary immunodeficiency, either due to malignancy, to chemotherapy, to an immunocompromised state post hematopoietic stem cell transplantation, or to treatment with anti-cytokine therapies. However, in the last decade, the study of patients affected by fungal infections without any overt risk factors has led to the unraveling of several monogenic defects of human immunity to fungi. The study of these inborn errors of immunity has added vastly to our comprehension of antifungal immunity. For example, the role of IL-17 immunity in human defense against mucocutaneous candidiasis has been extensively characterized through the analysis of IL-17F, IL-17RA, IL-17Rc, ACT1, RORγT and, indirectly, CARD9 deficiency.

Summary

Many monogenic causes of susceptibility to superficial and/or invasive fungal infections have been recently unraveled. Most of these inborn errors of immunity associate with a specific type of fungal infection, and such a defect should always be suspected and sought in patients affected by fungal infection in the absence of predisposing factors.
Literature
1.
Chastain DB, Henao-Martínez AF, Franco-Paredes C. Opportunistic invasive mycoses in AIDS: cryptococcosis, histoplasmosis, coccidiodomycosis, and talaromycosis. Curr Infect Dis Rep. 2017;19(10):36.PubMed
2.
Kullberg BJ, Arendrup MC. Invasive candidiasis. N Engl J Med. 2015;373(15):1445–56.PubMed
3.
Pana ZD, Roilides E, Warris A, Groll AH, Zaoutis T. Epidemiology of invasive fungal disease in children. J Pediatric Infect Dis Soc. 2017;6(suppl_1):S3–11.PubMedPubMedCentral
4.
•• Li J, Vinh DC, Casanova J-L, Puel A. Inborn errors of immunity underlying fungal diseases in otherwise healthy individuals. Curr Opin Microbiol. 2017;40:46–57 Comprehensive review of the disorders of Il-17 immunity and CARD9 deficiency underlying fungal infections. PubMed
5.
Lanternier F, Cypowyj S, Picard C, Bustamante J, Lortholary O, Casanova J-L, et al. Primary immunodeficiencies underlying fungal infections. Curr Opin Pediatr. 2013;25(6):736–47.PubMedPubMedCentral
6.
Vinh DC. Insights into human antifungal immunity from primary immunodeficiencies. Lancet Infect Dis. 2011;11(10):780–92.PubMed
7.
• Limon JJ, Skalski JH, Underhill DM. Commensal fungi in health and disease. Cell Host Microbe. 2017;22(2):156–65 Review of the commensal human mycobiota. PubMedPubMedCentral
8.
Brandt ME, Lockhart SR. Recent taxonomic developments with candida and other opportunistic yeasts. Curr Fungal Infect Rep. 2012;6(3):170–7.PubMedPubMedCentral
9.
• Fischer A, Notarangelo LD, Neven B, Cavazzana M, Puck JM. Severe combined immunodeficiencies and related disorders. Nat Rev Dis Primers. 2015;1:15061 Comprehensive review of the different genetic and phenotypic characteristics of SCID and CID. PubMed
10.
Dvorak CC, Cowan MJ, Logan BR, Notarangelo LD, Griffith LM, Puck JM, et al. The natural history of children with severe combined immunodeficiency: baseline features of the first fifty patients of the primary immune deficiency treatment consortium prospective study 6901. J Clin Immunol. 2013;33(7):1156–64.PubMedPubMedCentral
11.
Picard C, Casanova J-L, Puel A. Infectious diseases in patients with IRAK-4, MyD88, NEMO, or IκBα deficiency. Clin Microbiol Rev. 2011;24(3):490–7.PubMedPubMedCentral
12.
Schimke LF, Rieber N, Rylaarsdam S, Cabral-Marques O, Hubbard N, Puel A, et al. A novel gain-of-function IKBA mutation underlies ectodermal dysplasia with immunodeficiency and polyendocrinopathy. J Clin Immunol. 2013;33(6):1088–99.PubMed
13.
Hanson EP, Monaco-Shawver L, Solt LA, Madge LA, Banerjee PP, May MJ, et al. Hypomorphic nuclear factor-κB essential modulator mutation database and reconstitution system identifies phenotypic and immunologic diversity. J Allergy Clin Immunol. 2008;122(6):1169–1177.e16.PubMedPubMedCentral
14.
Aydin SE, Kilic SS, Aytekin C, Kumar A, Porras O, Kainulainen L, et al. DOCK8 deficiency: clinical and immunological phenotype and treatment options - a review of 136 patients. J Clin Immunol. 2015;35(2):189–98.PubMed
15.
Chu EY, Freeman AF, Jing H, Cowen EW, Davis J, Su HC, et al. Cutaneous manifestations of DOCK8 deficiency syndrome. Arch Dermatol. 2012;148(1):79–84.PubMed
16.
Engelhardt KR, Gertz ME, Keles S, Schäffer AA, Sigmund EC, Glocker C, et al. The extended clinical phenotype of 64 patients with dedicator of cytokinesis 8 deficiency. J Allergy Clin Immunol. 2015;136(2):402–12.PubMedPubMedCentral
17.
Spinner MA, Sanchez LA, Hsu AP, Shaw PA, Zerbe CS, Calvo KR, et al. GATA2 deficiency: a protean disorder of hematopoiesis, lymphatics, and immunity. Blood. 2014;123(6):809–21.PubMedPubMedCentral
18.
•• Okada S, Puel A, Casanova J-L, Kobayashi M. Chronic mucocutaneous candidiasis disease associated with inborn errors of IL-17 immunity. Clin Transl Immunology. 2016;5(12):e114 Comprehensive review of the defects of IL-17 immunity underlying CMC. PubMedPubMedCentral
19.
Puel A, Cypowyj S, Bustamante J, Wright JF, Liu L, Lim HK, et al. Chronic mucocutaneous candidiasis in humans with inborn errors of interleukin-17 immunity. Science. 2011;332(6025):65–8.PubMedPubMedCentral
20.
Boisson B, Wang C, Pedergnana V, Wu L, Cypowyj S, Rybojad M, et al. An ACT1 mutation selectively abolishes interleukin-17 responses in humans with chronic mucocutaneous candidiasis. Immunity. 2013;39(4):676–86.PubMed
21.
Ling Y, Cypowyj S, Aytekin C, Galicchio M, Camcioglu Y, Nepesov S, et al. Inherited IL-17RC deficiency in patients with chronic mucocutaneous candidiasis. J Exp Med. 2015;212(5):619–31.PubMedPubMedCentral
22.
Bader O, Weig MS, Gross U, Schön MP, Mempel M, Buhl T. A 32-year-old man with ulcerative mucositis, skin lesions, and nail dystrophy. Clin Infect Dis. 2012;54(7):1035–6.
23.
•• Lévy R, Okada S, Béziat V, Moriya K, Liu C, Chai LYA, et al. Genetic, immunological, and clinical features of patients with bacterial and fungal infections due to inherited IL-17RA deficiency. Proc Natl Acad Sci. 2016;113(51):E8277–85 Summary of the phenotype of patients with IL-17RA deficiency. PubMed
24.
Fellmann F, Angelini F, Wassenberg J, Perreau M, Ramirez NA, Simon G, et al. IL-17 receptor A and adenosine deaminase 2 deficiency in siblings with recurrent infections and chronic inflammation. J Allergy Clin Immunol. 2016;137(4):1189–1196.e2.PubMed
25.
Holland SM, DeLeo FR, Elloumi HZ, Hsu AP, Uzel G, Brodsky N, et al. STAT3 mutations in the hyper-IgE syndrome. N Engl J Med. 2007;357(16):1608–19.PubMed
26.
27.
Hambleton S, Salem S, Bustamante J, Bigley V, Boisson-Dupuis S, Azevedo J, et al. IRF8 mutations and human dendritic-cell immunodeficiency. N Engl J Med. 2011;365(2):127–38.PubMedPubMedCentral
28.
Glocker E-O, Hennigs A, Nabavi M, Schäffer AA, Woellner C, Salzer U, et al. A homozygous CARD9 mutation in a family with susceptibility to fungal infections. N Engl J Med. 2009;361(18):1727–35.PubMedPubMedCentral
29.
Okada S, Markle JG, Deenick EK, Mele F, Averbuch D, Lagos M, et al. Impairment of immunity to candida and mycobacterium in humans with bi-allelic RORC mutations. Science. 2015;349(6248):606–13.PubMedPubMedCentral
30.
•• Liu L, Okada S, Kong X-F, Kreins AY, Cypowyj S, Abhyankar A, et al. Gain-of-function human STAT1 mutations impair IL-17 immunity and underlie chronic mucocutaneous candidiasis. J Exp Med. 2011;208(8):1635–48 Characterization of the molecular defect of IL-17 immunity in STAT1 GOF mutations. PubMedPubMedCentral
31.
van de Veerdonk FL, Plantinga TS, Hoischen A, Smeekens SP, Joosten LAB, Gilissen C, et al. STAT1 mutations in autosomal dominant chronic mucocutaneous candidiasis. N Engl J Med. 2011;365(1):54–61.PubMed
32.
Puel A, Döffinger R, Natividad A, Chrabieh M, Barcenas-Morales G, Picard C, et al. Autoantibodies against IL-17A, IL-17F, and IL-22 in patients with chronic mucocutaneous candidiasis and autoimmune polyendocrine syndrome type I. J Exp Med. 2010;207(2):291–7.PubMedPubMedCentral
33.
•• Toubiana J, Okada S, Hiller J, Oleastro M, Gomez ML, Becerra JCA, et al. Heterozygous STAT1 gain-of-function mutations underlie an unexpectedly broad clinical phenotype. Blood. 2016;127(25):3154–64 Review of the clinical presentation of patients with STAT1 GOF. PubMedPubMedCentral
34.
Chandesris M-O, Melki I, Natividad A, Puel A, Fieschi C, Yun L, et al. Autosomal dominant STAT3 deficiency and hyper-IgE syndrome: molecular, cellular, and clinical features from a French national survey. Medicine (Baltimore). 2012;91(4):e1–e19.PubMedCentral
35.
de Beaucoudrey L, Samarina A, Bustamante J, Cobat A, Boisson-Dupuis S, Feinberg J, et al. Revisiting human IL-12Rβ1 deficiency: a survey of 141 patients from 30 countries. Medicine (Baltimore). 2010;89(6):381–402.
36.
Prando C, Samarina A, Bustamante J, Boisson-Dupuis S, Cobat A, Picard C, et al. Inherited IL-12p40 deficiency: genetic, immunologic, and clinical features of 49 patients from 30 Kindreds. Medicine (Baltimore). 2013;92(2):109–22.
37.
Ouederni M, Sanal O, Ikincioğullari A, Tezcan I, Dogu F, Sologuren I, et al. Clinical features of candidiasis in patients with inherited interleukin 12 receptor β1 deficiency. Clin Infect Dis. 2014;58(2):204–13.PubMed
38.
Lanternier F, Mahdaviani SA, Barbati E, Chaussade H, Koumar Y, Levy R, et al. Inherited CARD9 deficiency in otherwise healthy children and adults with Candida species–induced meningoencephalitis, colitis, or both. J Allergy Clin Immunol. 2015;135(6):1558–1568.e2.PubMedPubMedCentral
39.
Grumach AS, de Queiroz-Telles F, Migaud M, Lanternier F, Filho NR, Palma SMU, et al. A homozygous CARD9 mutation in a Brazilian patient with deep dermatophytosis. J Clin Immunol. 2015;35(5):486–90.PubMed
40.
41.
•• Lanternier F, Pathan S, Vincent QB, Liu L, Cypowyj S, Prando C, et al. Deep dermatophytosis and inherited CARD9 deficiency. N Engl J Med. 2013;369(18):1704–14 Landmark paper on CARD9 deficiency.
42.
Donadieu J, Fenneteau O, Beaupain B, Mahlaoui N, Chantelot CB. Congenital neutropenia: diagnosis, molecular bases and patient management. Orphanet J Rare Dis. 2011;6:26.PubMedPubMedCentral
43.
Hanna S, Etzioni A. Leukocyte adhesion deficiencies. Ann N Y Acad Sci. 2012;1250(1):50–5.PubMed
44.
Winkelstein JA, Marino MC, Johnston RB, Boyle J, Curnutte J, Gallin JI, et al. Chronic granulomatous disease: report on a national registry of 368 patients. Medicine (Baltimore). 2000;79(3):155–69.
45.
van den Berg JM, van Koppen E, Åhlin A, Belohradsky BH, Bernatowska E, Corbeel L, et al. Chronic granulomatous disease: the European experience. PLoS One. 2009;4(4):e5234.PubMedPubMedCentral
46.
Beauté J, Obenga G, Le Mignot L, Mahlaoui N, Bougnoux M-E, Mouy R, et al. Epidemiology and outcome of invasive fungal diseases in patients with chronic granulomatous disease: a multicenter study in France. Pediatr Infect Dis J. 2011;30(1):57–62.PubMed
47.
Drewniak A, Gazendam RP, Tool ATJ, van Houdt M, Jansen MH, van Hamme JL, et al. Invasive fungal infection and impaired neutrophil killing in human CARD9 deficiency. Blood. 2013;121(13):2385–92.PubMed
48.
Herbst M, Gazendam R, Reimnitz D, Sawalle-Belohradsky J, Groll A, Schlegel P-G, et al. Chronic Candida albicans meningitis in a 4-year-old girl with a homozygous mutation in the CARD9 gene (Q295X). Pediatr Infect Dis J. 2015;34(9):999–1002.PubMed
49.
• Kosmidis C, Denning DW. The clinical spectrum of pulmonary aspergillosis. Thorax. 2015;70(3):270–7 Comprehensive review of the clinical presentations of pulmonary aspergillosis. PubMed
50.
Vinh DC, Sugui JA, Hsu AP, Freeman AF, Holland SM. Invasive fungal disease in autosomal-dominant hyper-IgE syndrome. J Allergy Clin Immunol. 2010;125(6):1389–90.PubMedPubMedCentral
51.
52.
Segal BH, DeCarlo ES, Kwon-Chung KJ, Malech HL, Gallin JI, Holland SM. Aspergillus nidulans infection in chronic granulomatous disease. Medicine (Baltimore). 1998;77(5):345–54.
53.
Siddiqui S, Anderson VL, Hilligoss DM, Abinun M, Kuijpers TW, Masur H, et al. Fulminant mulch pneumonitis: an emergency presentation of chronic granulomatous disease. Clin Infect Dis. 2007;45(6):673–81.PubMed
54.
Rieber N, Gazendam RP, Freeman AF, Hsu AP, Collar AL, Sugui JA, et al. Extrapulmonary aspergillus infection in patients with CARD9 deficiency. JCI Insight. 2016;1(17):e89890.PubMedPubMedCentral
55.
Cheikhrouhou F, Makni F, Ayadi A. La maladie dermatophytique: revue de la littérature. J Mycol Médicale. 2010;20(1):61–9.
56.
Jachiet M, Lanternier F, Rybojad M, Bagot M, Ibrahim L, Casanova J-L, et al. Posaconazole treatment of extensive skin and nail dermatophytosis due to autosomal recessive deficiency of CARD9. JAMA Dermatol. 2015;151(2):192–4.PubMed
57.
Boudghene Stambouli O, Amrani N, Boudghéne Stambouli K, Bouali F. Dermatophytic disease with deficit in CARD9: a new case with a brain impairment. J Mycol Médicale. 2017;27(2):250–3.
58.
Yan XX, Yu CP, Fu XA, Bao FF, Du DH, Wang C, et al. CARD9 mutation linked to Corynespora cassiicola infection in a Chinese patient. Br J Dermatol. 2015;174(1):176–9.PubMed
59.
Wang X, Wang W, Lin Z, Wang X, Li T, Yu J, et al. CARD9 mutations linked to subcutaneous phaeohyphomycosis and TH17 cell deficiencies. J Allergy Clin Immunol. 2014;133(3):905–908.e3.PubMed
60.
Lanternier F, Barbati E, Meinzer U, Liu L, Pedergnana V, Migaud M, et al. Inherited CARD9 deficiency in 2 unrelated patients with invasive Exophiala infection. J Infect Dis. 2015;211(8):1241–50.PubMed
61.
Wang X, Zhang R, Wu W, Song Y, Wan Z, Han W, et al. Impaired specific antifungal immunity in CARD9-deficient patients with phaeohyphomycosis. J Investig Dermatol. 2018;138(3):607–17.PubMed
62.
Leven EA, Maffucci P, Ochs HD, Scholl PR, Buckley RH, Fuleihan RL, et al. Hyper IgM syndrome: a report from the USIDNET registry. J Clin Immunol. 2016;36(5):490–501.PubMedPubMedCentral
63.
Winkelstein JA, Marino MC, Ochs H, Fuleihan R, Scholl PR, Geha R, et al. The X-linked hyper-IgM syndrome: clinical and immunologic features of 79 patients. Medicine (Baltimore). 2003;82(6):373–84.
64.
Su HC, Jing H, Zhang Q. DOCK8 deficiency. Ann N Y Acad Sci. 2012;1246(1):26–33.
65.
Hanna S, Etzioni A. MHC class I and II deficiencies. J Allergy Clin Immunol. 2014;134(2):269–75.PubMed
66.
Sullivan KE, Mullen CA, Blaese RM, Winkelstein JA. A multiinstitutional survey of the Wiskott-Aldrich syndrome. J Pediatr. 1994;125(6, Part 1):876–85.PubMed
67.
Dokal I. Dyskeratosis congenita. In: Sullivan KE, Stiehm ER, editors. Stiehm’s immune deficiencies. Cambridge: Academic; 2014.
68.
Ming EJ, Graham JMJ. Genetic syndromes with evidence of immune deficiency. In: Sullivan KE, Stiehm ER, editors. Stiehm’s immune deficiencies. Cambridge: Academic; 2014.
69.
Ziegler JB, Kashef S. Well-known combined immune deficiency syndromes. In: Sullivan KE, Stiehm ER, editors. Stiehm’s immune deficiencies. Cambridge: Academic; 2014.
70.
Su HC, Lenardo MJ. Combined immune deficiencies. In: Sullivan KE, Stiehm ER, editors. Stiehm’s immune deficiencies. Cambridge: Academic; 2014.
71.
Sirianni MC, Atzori C, De Santis W, Milito C, Esposito A, Marziali M, et al. A case of Pneumocystis jiroveci pneumonia in X-linked agammaglobulinaemia treated with immunosuppressive therapy: a lesson for immunologists. Int Arch Allergy Immunol. 2006;140(1):82–8.PubMed
72.
Walzer PD, Schultz MG, Western KA, Robbins JB. Pneumocystis carinii pneumonia and primary immune deficiency diseases of infancy and childhood. J Pediatr. 1973;82(3):416–22.PubMed
73.
Lee PP, Lau Y-L. Cellular and molecular defects underlying invasive fungal infections—revelations from endemic mycoses. Front Immunol. 2017;8:735.PubMedPubMedCentral
74.
Odio CD, Marciano BE, Galgiani JN, Holland SM. Risk Factors for disseminated coccidioidomycosis, United States. Emerg Infect Dis. 2017;23(2).
75.
Vinh DC, Masannat F, Dzioba RB, Galgiani JN, Holland SM. Refractory disseminated coccidioidomycosis and mycobacteriosis in interferon-γ receptor 1 deficiency. Clin Infect Dis. 2009;49(6):e62–5.PubMedPubMedCentral
76.
Vinh DC, Schwartz B, Hsu AP, Miranda DJ, Valdez PA, Fink D, et al. Interleukin-12 receptor β1 deficiency predisposing to disseminated coccidioidomycosis. Clin Infect Dis. 2011;52(4):e99–102.PubMedPubMedCentral
77.
Zerbe CS, Holland SM. Disseminated histoplasmosis in persons with interferon-γ receptor 1 deficiency. Clin Infect Dis. 2005;41(4):38–41.
78.
Odio CD, Lee Milligan K, McGowan K, Rudman Spergel AK, Bishop R, Boris L, et al. Endemic mycoses in patients with STAT3-mutated hyper-IgE (Job) syndrome. J Allergy Clin Immunol. 2015;136(5):1411–1413.e2.PubMedPubMedCentral
79.
Powers AE, Bender JM, Kumánovics A, Ampofo K, Augustine N, Pavia AT, et al. Coccidioides immitis meningitis in a patient with hyperimmunoglobulin E syndrome due to a novel mutation in signal transducer and activator of transcription. Pediatr Infect Dis J. 2009;28(7):664–6.PubMed
80.
Sampaio EP, Hsu AP, Pechacek J, Bax HI, Dias DL, Paulson ML, et al. Signal transducer and activator of transcription 1 (STAT1) gain-of-function mutations and disseminated coccidioidomycosis and histoplasmosis. J Allergy Clin Immunol. 2013;131(6):1624–1634.e17.PubMedPubMedCentral
81.
Spinner MA, Ker JP, Stoudenmire CJ, Fadare O, Mace EM, Orange JS, et al. GATA2 deficiency underlying severe blastomycosis and fatal herpes simplex virus–associated hemophagocytic lymphohistiocytosis. J Allergy Clin Immunol. 2016;137(2):638–40.PubMed
82.
Tu RK, Peters ME, Gourley GR, Hong R. Esophageal histoplasmosis in a child with immunodeficiency with hyper-IgM. Am J Roentgenol. 1991;157(2):381–2.
83.
Hostoffer RW, Berger M, Clark HT, Schreiber JR. Disseminated histoplasma capsulatum in a patient with hyper IgM immunodeficiency. Pediatrics. 1994;94(2):234–6.PubMed
84.
Yilmaz GG, Yilmaz E, Coşkun M, Karpuzoǧlu G, Gelen T, Yeǧin O. Cutaneous histoplasmosis in a child with hyper-IgM. Pediatr Dermatol. 1995;12(3):235–8.PubMed
85.
• Lovell JP, Foruraghi L, Freeman AF, Uzel G, Zerbe CS, Su H, et al. Persistent nodal histoplasmosis in NF-κB essential modulator (NEMO) deficiency: report of a case and review of infection in primary immunodeficiencies. J Allergy Clin Immunol. 2016;138(3):903–5 Review of all published cases of histoplasmosis in patients with PIDs. PubMedPubMedCentral
86.
Duncan RA, von Reyn CF, Alliegro GM, Toossi Z, Sugar AM, Levitz SM. Idiopathic CD4+ T-lymphocytopenia--four patients with opportunistic infections and no evidence of HIV infection. N Engl J Med. 1993;328(6):393–8.PubMed
87.
Spira TJ, Jones BM, Nicholson JK, Lal RB, Rowe T, Mawle AC, et al. Idiopathic CD4+ T-lymphocytopenia--an analysis of five patients with unexplained opportunistic infections. N Engl J Med. 1993;328(6):386–92.PubMed
88.
Relia N, Kavimandan A, Sinha S, Sharma SK. Disseminated histoplasmosis as the first presentation of idiopathic CD4+ T-lymphocytopenia. J Postgrad Med. 2010;56(1):39–40.PubMed
89.
90.
Mellouli F, Ksouri H, Barbouche R, Maamer M, Hamed LB, Hmida S, et al. Successful treatment of fusarium solani ecthyma gangrenosum in a patient affected by leukocyte adhesion deficiency type 1 with granulocytes transfusions. BMC Dermatol. 2010;10:10.PubMedPubMedCentral
91.
Moroti RV, Gheorghita V, Al-Hatmi AMS, de Hoog GS, Meis JF, Netea MG. Fusarium ramigenum, a novel human opportunist in a patient with common variable immunodeficiency and cellular immune defects: case report. BMC Infect Dis. 2016;16:79.PubMedPubMedCentral
92.
Wang X, Lin Z, Gao L, Wang A, Wan Z, Chen W, et al. Exome sequencing reveals a signal transducer and activator of transcription 1 (STAT1) mutation in a child with recalcitrant cutaneous fusariosis. J Allergy Clin Immunol. 2013;131(4):1242–3.PubMed
93.
Okura Y, Kawamura N, Okano M, Toita N, Takezaki S, Yamada M, et al. Fusarium falciforme infection in a patient with chronic granulomatous disease: unique long-term course of epidural abscess. Pediatr Int. 2015;57(1):e4–6.PubMed
94.
Rajasingham R, Smith RM, Park BJ, Jarvis JN, Govender NP, Chiller TM, et al. Global burden of disease of HIV-associated cryptococcal meningitis: an updated analysis. Lancet Infect Dis. 2017;17(8):873–81.PubMedPubMedCentral
95.
Levy J, Espanol-Boren T, Thomas C, Fischer A, Tovo P, Bordigoni P, et al. Clinical spectrum of X-linked hyper-IgM syndrome. J Pediatr. 1997;131(1 Pt 1):47–54.PubMed
96.
Malheiro L, Lazzara D, Xerinda S, Pinheiro MD, Sarmento A. Cryptococcal meningoencephalitis in a patient with hyper immunoglobulin M (IgM) syndrome: a case report. BMC Res Notes. 2014;7:566.PubMedPubMedCentral
97.
Mitsui-Sekinaka K, Imai K, Sato H, Tomizawa D, Kajiwara M, Nagasawa M, et al. Clinical features and hematopoietic stem cell transplantations for CD40 ligand deficiency in Japan. J Allergy Clin Immunol. 2015;136(4):1018–24.PubMed
98.
França TT, Leite LFB, Maximo TA, Lambert CG, Zurro NB, Forte WCN, et al. A novel de novo mutation in the CD40 ligand gene in a patient with a mild X-linked hyper-IgM phenotype initially diagnosed as CVID: new aspects of old diseases. Front Pediatr. 2018;6:130.PubMedPubMedCentral
99.
Lee M-Y, Chung J-H, Shin J-H, Hwang T-J, Kim K-S, Lee J-H, et al. Lymphonodular cryptococcosis diagnosed by fine needle aspiration cytology in hyper-IgM syndrome. Acta Cytol. 2001;45(2):241–4.PubMed
100.
Jo EK, Kim HS, Lee MY, Iseki M, Lee JH, Song CH, et al. X-linked hyper-IgM syndrome associated with Cryptosporidium parvum and Cryptococcus neoformans infections: the first case with molecular diagnosis in Korea. J Korean Med Sci. 2002;17(1):116–20.PubMedPubMedCentral
101.
Zonios DI, Falloon J, Huang C-Y, Chaitt D, Bennett JE. Cryptococcosis and idiopathic CD4 lymphocytopenia. Medicine (Baltimore). 2007;86(2):78–92.
102.
Vinh DC, Patel SY, Uzel G, Anderson VL, Freeman AF, Olivier KN, et al. Autosomal dominant and sporadic monocytopenia with susceptibility to mycobacteria, fungi, papillomaviruses, and myelodysplasia. Blood. 2010;115(8):1519–29.PubMedPubMedCentral
103.
Panackal AA, Rosen LB, Uzel G, Davis MJ, Hu G, Adeyemo A, et al. Susceptibility to cryptococcal meningoencephalitis associated with idiopathic CD4+ lymphopenia and secondary germline or acquired defects. Open Forum Infect Dis. 2017;4(2):oxf082.
104.
Rosen LB, Freeman AF, Yang LM, Jutivorakool K, Olivier KN, Angkasekwinai N, et al. Anti–GM-CSF autoantibodies in patients with cryptococcal meningitis. J Immunol. 2013;190(8):3959–66.PubMedPubMedCentral
105.
Kuo C-Y, Wang S-Y, Shih H-P, Tu K-H, Huang W-C, Ding J-Y, et al. Disseminated cryptococcosis due to anti-granulocyte-macrophage colony-stimulating factor autoantibodies in the absence of pulmonary alveolar proteinosis. J Clin Immunol. 2017;37(2):143–52.PubMed
106.
Browne SK, Burbelo PD, Chetchotisakd P, Suputtamongkol Y, Kiertiburanakul S, Shaw PA, et al. Adult-onset immunodeficiency in Thailand and Taiwan. N Engl J Med. 2012;367(8):725–34.PubMedPubMedCentral
107.
Mourad A, Perfect JR. Present and future therapy of cryptococcus infections. J Fungi. 2018;4(3):79.
Metadata
Title
Patients with Primary Immunodeficiencies: How Are They at Risk for Fungal Disease?
Authors
Giorgia Bucciol
Leen Moens
Isabelle Meyts
Publication date
01-12-2018
Publisher
Springer US
Published in
Current Fungal Infection Reports / Issue 4/2018
Print ISSN: 1936-3761
Electronic ISSN: 1936-377X
DOI
https://doi.org/10.1007/s12281-018-0323-z

Other articles of this Issue 4/2018

Current Fungal Infection Reports 4/2018 Go to the issue

Current Management of Fungal Infections (J Maertens, Section Editor)

Invasive Mold Infections in Patients with Chronic Lymphoproliferative Disorders

Current Management of Fungal Infections (J Maertens, Section Editor)

Diagnosing Invasive Mold Infections: What Is Next

Correction

Correction to: Pressing Priorities for Mycetoma Control and Prevention

Fungal Infections of Skin and Subcutaneous (A Bonifaz, Section Editor)

Association of Malassezia to Atopic Dermatitis

Clinical Mycology Lab Issues (S Córdoba, Section Editor)

Fungal Keratitis: Epidemiological Profile in Argentina

Clinical Mycology Lab Issues (S Córdoba, Section Editor)

Emergence of Resistance to Fluconazole in Candida albicans Isolated From Vaginal Discharge
Obesity Clinical Trial Summary

At a glance: The STEP trials

Read more

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Pediatric Cardiology Video

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

Cardiopulmonary Comorbidity Video

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Valvular Heart Disease Video

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Heart Failure Video

Watch this official video from ACC.24. Dr. Biykem Bozkurt discuss last year's major advances in heart failure and cardiomyopathies.

ACC 2024 Congress Coverage

Heart Failure Video

Year in Review: Heart failure and cardiomyopathies

Watch now

Watch this official video from ACC.24. Dr. Biykem Bozkurt discuss last year's major advances in heart failure and cardiomyopathies.

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

16-04-2024 Type 2 Diabetes News

Incentivised to exercise

11-04-2024 Lifestyle Modifications News

New intervention for STEMI-related cardiogenic shock

10-04-2024 Myocardial Infarction News

» View more highlights on the ACC 2024 congress hub page

Image Credits